Cleanroom Certification and Airflow Visualization: The SCA Letter

On 14 September 2026, the United States Food and Drug Administration issued warning letter number 724202 to SCA Pharmaceuticals, a registered 503B outsourcing facility in Little Rock, Arkansas. The letter is a clear statement of what FDA now expects from any sterile manufacturer or compounder: a cleanroom is only as good as the evidence that it is still performing. FDA found that SCA's ISO 5 areas, the cleanest zones where sterile products are exposed, lacked routine certification and lacked airflow visualization studies performed under dynamic, in-use conditions.

For Canadian sterile drug makers, compounders and companies exporting injectables to the United States or Europe, the SCA letter maps directly onto Health Canada's Annex 1 and EU GMP Annex 1. The expectations are the same: classify the air, prove the airflow protects the product, qualify incoming components and demonstrate sound aseptic technique. This article explains each finding, the standards behind it, and a practical checklist to confirm your cleanroom qualification would survive an inspection.

What the SCA warning letter says

The warning letter cites SCA Pharmaceuticals for cGMP deficiencies in sterile drug production at its Little Rock facility. FDA inspected the site from 20 to 30 October 2025, reviewed two responses dated 21 November and 31 December 2025, and found both insufficient. The findings centre on cleanroom control: ISO 5 areas were not routinely certified, airflow was not visualized under dynamic conditions, microbial contamination in the aseptic zone was not adequately investigated, foreign material was found in syringes, and aseptic technique introduced contamination risk.

As a 503B outsourcing facility, SCA must meet full cGMP under 21 CFR Parts 210 and 211, not the lesser standards that apply to traditional 503A pharmacy compounding. FDA cited 21 CFR 211.192 among other requirements. The letter is part of a clear 2026 enforcement pattern around sterile and aseptic manufacturing, the same theme seen in FDA's recent action on media fill failures and aseptic process simulation.

ISO 5, Grade A and what certification really means

ISO 5, equivalent to EU GMP Grade A, is the cleanest classification, used for the critical zone where sterile product and open containers are exposed. Certification means proving, on a defined schedule, that the area still meets its classification and that the airflow still protects the product. A one-time qualification at build is not certification. FDA faulted SCA because its ISO 5 areas were not routinely re-certified.

Certification is a package of tests, not a single particle count. It confirms air cleanliness by particle concentration under ISO 14644-1, airflow velocity and uniformity, HEPA filter integrity, room pressure cascades, recovery after a disturbance, and airflow visualization. Each test has a defined acceptance criterion and a frequency driven by risk. When any element lapses, the manufacturer can no longer claim the environment is in a state of control.

Airflow visualization under dynamic conditions

Airflow visualization, often called a smoke study, uses a visible medium to show that unidirectional air sweeps the critical zone and carries particles away from exposed product. FDA requires it under dynamic conditions, meaning with operators and equipment moving as they do in real production. SCA's studies did not meet this expectation, so the company could not prove its airflow protected the product during actual operations.

A static smoke study done in an empty room proves very little. The risk to a sterile product comes from the turbulence created by people, carts, equipment and interventions. FDA, Health Canada Annex 1 and EU GMP Annex 1 all expect visualization that captures those dynamics, that is recorded, reviewed and repeated after significant changes. Our guide to the Annex 1 contamination control strategy explains how airflow visualization fits the wider strategy an inspector expects to see.

Microbial contamination and the 211.192 investigation

When environmental monitoring recovers microorganisms in an aseptic zone, 21 CFR 211.192 requires a thorough investigation of the effect on product quality, extending to other batches and products. FDA found that SCA recovered contamination in its aseptic processing area without adequate evaluation or corrective action. A recovery with no robust investigation is a finding waiting to happen.

The expectation is clear: identify the organism, assess the batches at risk, decide disposition with documented justification, find the root cause and correct it. A pattern of recoveries without that discipline tells an inspector the quality unit is not in control of the aseptic environment. Our guide to getting 21 CFR 211.192 right walks through a defensible investigation, and our analysis of a GLP-1 compounding warning letter shows how aseptic and data integrity gaps compound each other.

Incoming component inspection and aseptic technique

FDA found foreign material between the stopper ribs of syringes, which it tied to inadequate incoming component inspection and product-contact surface control. It also observed aseptic technique that introduced contamination risk into critical zones, citing a specific compounded product. Both findings point to controls that protect the product at the point of exposure.

Incoming component inspection must be defined, risk-based and documented, with clear acceptance criteria and handling that keeps particles out of the fill. Aseptic technique must be trained, qualified and monitored, because the operator is the greatest contamination risk in any Grade A zone. The example product FDA named, a fentanyl citrate with bupivacaine admixture, is exactly the kind of high-risk sterile preparation where a single lapse can reach a patient.

Cleanroom certification and aseptic control checklist

Use this self-check to test whether your cleanroom qualification and aseptic controls would survive an inspection. It is the basis of the free lead magnet below.

• Every ISO 5 or Grade A area is on a documented certification schedule with current, in-date results.
• Particle classification under ISO 14644-1 is performed both at rest and in operation.
• Airflow velocity, uniformity and HEPA filter integrity are tested and within acceptance criteria.
• Airflow visualization studies are performed under dynamic conditions, recorded and reviewed.
• Room pressure differentials are continuously monitored with alarms.
• Recovery testing confirms the area returns to its classification after a disturbance.
• Environmental monitoring recoveries trigger a 21 CFR 211.192-style investigation with disposition and root cause.
• Incoming components are inspected against documented, risk-based acceptance criteria.
• Aseptic technique is trained, qualified by media fill, and monitored by routine observation.
• Requalification is triggered by changes, adverse trends and defined time intervals.

Common mistakes that lead to a cleanroom finding

• Treating qualification as a one-time event. Build-time qualification is not ongoing certification, and FDA expects current data.
• Smoke studies in an empty room. Static visualization misses the turbulence that real operations create.
• Logging recoveries without investigating. A microbial recovery with no 211.192 investigation is an open finding.
• Assuming 503A rules apply. A 503B outsourcing facility must meet full cGMP, not pharmacy compounding standards.
• Skipping incoming component inspection. Foreign material in product-contact components can reach the patient.
• Training aseptic technique once. Technique must be re-qualified and monitored, not assumed to hold.

Frequently asked questions

What is cleanroom certification?

Cleanroom certification is the scheduled testing that proves a cleanroom still meets its classification and that its airflow still protects the product. It includes particle counts under ISO 14644-1, airflow velocity and uniformity, HEPA filter integrity, pressure differentials, recovery testing and airflow visualization. It is ongoing, not a one-time qualification at installation.

How often must an ISO 5 cleanroom be certified?

Frequency is risk-based, but ISO 14644-1 and industry practice set a short interval for the cleanest grades. ISO 5 particle classification is commonly confirmed at least every six months, HEPA integrity at least annually, and airflow visualization at qualification and after significant changes. Health Canada and EU GMP Annex 1 expect the schedule to be justified and documented, with continuous monitoring of the critical parameters.

What is airflow visualization under dynamic conditions?

It is a smoke study performed with operators, equipment and interventions moving as they do in production, rather than in a static empty room. It shows whether unidirectional air sweeps the critical zone and carries particles away from exposed product during real operations. FDA faulted SCA because its studies did not demonstrate this.

What is a 503B outsourcing facility?

A 503B outsourcing facility is a compounder registered with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. Unlike a traditional 503A pharmacy, it must comply with full cGMP under 21 CFR Parts 210 and 211, including sterile manufacturing controls, which is why SCA was held to that standard.

Why does foreign material in syringes matter?

Foreign material in a product-contact component such as a syringe can become particulate matter in an injectable, which is a direct patient safety hazard. FDA tied SCA's finding to inadequate incoming component inspection. Robust, documented inspection of incoming components with clear acceptance criteria is a cGMP expectation.

How does the SCA letter apply to Canadian manufacturers?

Canadian sterile drug makers and exporters are inspected against Health Canada's Annex 1 (GUI-0119) and, for European markets, EU GMP Annex 1. Both require cleanroom classification, qualified airflow, filter integrity, environmental monitoring investigations and aseptic technique controls. A gap FDA cited at SCA would be cited by a Health Canada or EU inspector. Our 25-point Health Canada GMP self-assessment is a useful starting point.

How MFLRC can help

MFLRC helps sterile manufacturers and compounders build cleanroom qualification and requalification programs that stand up to inspection. We design environmental monitoring and certification schedules, plan and review airflow visualization studies under dynamic conditions, build 21 CFR 211.192 investigation and CAPA systems, strengthen incoming component inspection, and run aseptic technique and media fill programs. Our team includes a Health Canada security-cleared, approved Quality Assurance Person, and we support GMP and EU-GMP gap assessments, validation master planning, SOP development, and mock FDA and Health Canada audits.

If you run ISO 5 or Grade A areas, book a 30-minute cleanroom and aseptic readiness review. We will check your certification schedule, airflow visualization and environmental monitoring against Annex 1 and FDA expectations before an inspector does.

Conclusion

The SCA warning letter is a reminder that a cleanroom is a claim you have to keep proving. FDA, Health Canada and the European Union all expect current certification data, airflow visualization under real operating conditions, disciplined investigation of every microbial recovery, and controlled components and technique. Sterile manufacturers that treat qualification as a living program, not a one-time milestone, are the ones that keep their products and their licences safe. The evidence an inspector wants is the evidence you should already be collecting.

Sources and references

• FDA, Warning Letters database (SCA Pharmaceuticals, LLC, WL number 724202)
• eCFR, 21 CFR 211.192 Production record review
• ISO 14644-1, Cleanrooms and associated controlled environments, Classification of air cleanliness by particle concentration
• Health Canada, Annex 1 to the GMP Guide, Manufacture of sterile drugs (GUI-0119)
• European Commission, EudraLex Volume 4, Annex 1 Manufacture of Sterile Medicinal Products
• FDA, Sterile Drug Products Produced by Aseptic Processing, Current Good Manufacturing Practice (2004)